Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

Is K-ras Gene Mutation a Prognostic Factor for Colorectal Cancer

(2012) JiaoJiao Ren et al.   DISEASES OF THE COLON & RECTUM

Combined Phosphatase and Tensin Homolog (PTEN) Loss and Fatty Acid Synthase (FAS) Overexpression Worsens the Prognosis of Chinese Patients with Hepatocellular Carcinoma

(2012) Xuehua Zhu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Systematic Review and Meta-analysis of the Influence of HER2 Expression and Amplification in Operable Oesophageal Cancer

(2012) David S. Y. Chan et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer

(2012) Britta Weigelt et al.   Frontiers in Oncology

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

(2011) E. Bria et al.   ANNALS OF ONCOLOGY

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Targeted therapies: how personal should we go?

(2011) Miriam Martini et al.   Nature Reviews Clinical Oncology

Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status:In silicoand Biological Evaluations

(2010) Shingo Dan et al.   CANCER RESEARCH

Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib

(2010) F Stegmeier et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple abnormalities of myocardial insulin signaling in a porcine model of diet-induced obesity

(2009) Jenny Lee et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

(2009) Krishna M. Vasudevan et al.   CANCER CELL

Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis

(2009) Gaëtan Des Guetz et al.   EUROPEAN JOURNAL OF CANCER

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

(2009) Fotios Loupakis et al.   JOURNAL OF CLINICAL ONCOLOGY

PIK3CA alterations in Middle Eastern ovarian cancers

(2009) Jehad Abubaker et al.   Molecular Cancer

Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors

(2009) Fatima Haggar et al.   Clinics in Colon and Rectal Surgery

PTEN and the PI3-Kinase Pathway in Cancer

(2008) Nader Chalhoub et al.   Annual Review of Pathology-Mechanisms of Disease

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

The PTEN–PI3K pathway: of feedbacks and cross-talks

(2008) A Carracedo et al.   ONCOGENE

TRARESA: a tissue microarray-based hospital system for biomarker validation and discovery

(2008) Kakoli Das et al.   PATHOLOGY